Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

APELIN THERAPY

Financiado

Cerrado

Apelin inhibition as an anti cancer therapy

The spread of cancer is a major cause of mortality and morbidity throughout Europe and beyond. As the growth of solid tumours is dependent on the formation of a neovascular supply, inhibition of tumour-induced neoangiogenesis repr... ver más

31/01/2016

IMBA

179K€

Presupuesto del proyecto: 179K€

Líder del proyecto

INSTITUT FUER MOLEKULARE BIOTECHNOLOGIE GMBH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-01-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

IMBA

0.00€ | Lider

Proyectos interesantes

HALLMARKS-TO-THERAPY

Medical Technol...

Applied Physics

3M€ Cerrado

RTI2018-098968-B-I00

Medical Technol...

Applied Physics

242K€ Cerrado

LEUKEMIA AND VEGF

Medical Technol...

Applied Physics

100K€ Cerrado

SAF2012-36575

Medical Technol...

Cancer Research

193K€ Cerrado

SAF2017-89299-P

Medical Technol...

Applied Physics

327K€ Cerrado

EC-InterCom

Medical Technol...

Applied Physics

166K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

INSTITUT FUER MOLEKULARE BIOTECHNOLOGIE GMBH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 179K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The spread of cancer is a major cause of mortality and morbidity throughout Europe and beyond. As the growth of solid tumours is dependent on the formation of a neovascular supply, inhibition of tumour-induced neoangiogenesis represents an actively pursued strategy to treat human cancers. Current anti-angiogenic therapies are, however, hampered by the onset of resistance through upregulation of additional angiogenesis factors. Therefore, the identification and study of these alternative neo-angiogenesis regulators as therapeutic targets is currently of key interest. Apelin is a potent angiogenic factor frequently found upregulated in cancer. However, the in vivo pathophysiological relevance of apelin function in cancer has not been addressed so far. In this proposal, we intend to study apelin inhibition and function in spontaneous cancer models. We will take a multidisciplinary and entirely in vivo approach that will combine the power of mouse genetics with state-of-the-art analysis techniques. We will evaluate in parallel the function of apelin in cancer and the highly promising effectiveness of apelin inhibition as a therapeutic cancer target either alone or in a combined anti-angiogenesis therapy. The relevance of de novo formation of lymphatic vessels in the progression of cancer has only recently been recognized. Using state-of-the-art techniques we will extend our studies by not only assessing the in vivo role of apelin in angiogenesis but also its involvement in lymphangiogenesis. Taken together, we believe that this project will shed new light on the role and function of a novel factor that regulates vessel formation in cancer and validate its potential as therapeutic target. If successful, our in vivo multidisciplinary study will open a new avenue for the treatment of resistant cancer cases and for the development of combinatorial anti-cancer therapies with higher efficiency and a reduced incidence of resistance formation.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores